15:40 , May 10, 2019 |  BC Extra  |  Clinical News

Polyphor valuation cut in half on halted Phase IIIs of antibiotic murepavadin

Polyphor lost CHF12.27 (48%) to CHF13.38 on Friday after announcing late Thursday that it suspended enrollment in a pair of Phase III trials of pneumonia antibiotic murepavadin (POL7080) after observing a higher-than-expected incidence of acute...
19:44 , May 9, 2019 |  BC Extra  |  Clinical News

May 9 Clinical Quick Takes: Polyphor, BMS, Cel-Sci, University of Pittsburgh, Merck, Scholar Rock, Promethera

Polyphor halts Phase III enrollment of pneumonia therapy  Polyphor Ltd. (SIX:POLN) said late Thursday it will suspend enrollment in the Phase III PRISM-MDR and PRISM-UDR trials of pneumonia antibiotic murepavadin (POL7080) after observing a 56%...
23:05 , May 2, 2019 |  BC Innovations  |  Translation in Brief

Public funding highlights

Public funding highlights Selected developments and initiatives in 1Q19 from major sources of public funding including National Institutes of Health (NIH), the U.K.’s Medical Research Council (MRC), the Innovative Medicines Initiative (IMI), the Canadian Institutes...
20:38 , Apr 9, 2019 |  BC Extra  |  Company News

Management tracks: Cyclerion, Alkermes, Alder

A week after completing its spinout from Ironwood, Cyclerion has hired Andreas Busch as chief innovation officer. Busch was EVP, head of R&D and CSO at Shire plc and previously served as EVP, head of...
17:09 , Jan 25, 2019 |  BC Week In Review  |  Financial News

Novo's REPAIR fund investments total €18M in 2018

Novo Holdings A/S (Hellerup, Denmark) said its REPAIR Impact Fund invested in antibacterial companies Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), MinervaX ApS (Copenhagen, Denmark) and Procarta Biosystems Ltd. (Norwich, U.K.), bringing the fund's 2018 total investment...
22:52 , Oct 26, 2018 |  BC Extra  |  Company News

Management tracks: Principia, Orexo, Polyphor, MeiraGTx

Immunology and oncology company Principia Biopharma Inc. (NASDAQ:PRNB) hired Dolca Thomas as CMO. She succeeds Steve Gourlay, who will remain as a senior medical adviser through mid-2019. Thomas was VP and global head of translational...
18:07 , Sep 7, 2018 |  BC Week In Review  |  Financial News

Novo's REPAIR fund makes first investment in Swiss antibiotic company

Novo Holdings A/S invested CHF6.8 million ($7 million) on Sept. 6 into antibiotic company Polyphor Ltd. (SIX:POLN) through the purchase of 178,947 new shares at CHF38. The funds come from Novo's REPAIR Impact Fund, which...
00:00 , Aug 11, 2018 |  BioCentury  |  Product Development

Exacerbation management

Based on work spearheaded by the Cystic Fibrosis Foundation, Corbus Pharmaceuticals Holdings Inc. will be the first company to attempt to gain approval in CF based on pulmonary exacerbations instead of FEV1. The company is...
23:21 , Jul 13, 2018 |  BioCentury  |  Finance

Pause for politics

The near record-setting pace of 1H18 capital markets activity isn’t likely to be replicated this half, but that won’t be because of changes to sector fundamentals. Instead, it’s likely the consequence of macroeconomic and geopolitical...
02:30 , May 18, 2018 |  BC Week In Review  |  Financial News

Polyphor raises $155.3M Swiss IPO

Polyphor Ltd. (SIX:POLN) gained CHF0.20 to CHF38.20 in its first day of trading on May 15 after raising CHF155 million ($155.3 million) through the sale of 4.1 million shares at CHF38 in an IPO on...